A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonist
- 31 July 1998
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 102 (1), 50-56
- https://doi.org/10.1016/s0091-6749(98)70054-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Pharmacology of montelukast sodium (Singulair™), a potent and selective leukotriene D4 receptor antagonistCanadian Journal of Physiology and Pharmacology, 1995
- Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthmaJournal of Allergy and Clinical Immunology, 1994
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994
- Leukotriene E4 and granulocytic infiltration into asthmatic airwaysThe Lancet, 1993
- Do leukotrienes play a role in the regulation of proliferation of normal and leukemic hemopoietic cells?Prostaglandins, Leukotrienes & Essential Fatty Acids, 1993
- Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.Thorax, 1993
- Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.Thorax, 1992
- Eosinophilic Inflammation in AsthmaNew England Journal of Medicine, 1990
- High-dose inhaled steroid therapy for asthmaJournal of Allergy and Clinical Immunology, 1989
- Leukotrienes are potent constrictors of human bronchiNature, 1980